Literature DB >> 27579996

Design of Polyelectrolyte Multilayers to Promote Immunological Tolerance.

Lisa H Tostanoski1, Yu-Chieh Chiu1, James I Andorko1, Ming Guo2, Xiangbin Zeng1, Peipei Zhang1, Walter Royal2, Christopher M Jewell1,3,4,5.   

Abstract

Recent studies demonstrate that excess signaling through inflammatory pathways (e.g., toll-like receptors, TLRs) contributes to the pathogenesis of human autoimmune diseases, including lupus, diabetes, and multiple sclerosis (MS). We hypothesized that codelivery of a regulatory ligand of TLR9, GpG oligonucleotide, along with myelin-the "self" molecule attacked in MS-might restrain the pro-inflammatory signaling typically present during myelin presentation, redirecting T cell differentiation away from inflammatory populations and toward tolerogenic phenotypes such as regulatory T cells. Here we show that myelin peptide and GpG can be used as modular building blocks for co-assembly into immune polyelectrolyte multilayers (iPEMs). These nanostructured capsules mimic attractive features of biomaterials, including tunable cargo loading and codelivery, but eliminate all carriers and synthetic polymers, components that often exhibit intrinsic inflammatory properties that could exacerbate autoimmune disease. In vitro, iPEMs assembled from myelin and GpG oligonucleotide, but not myelin and a control oligonucleotide, restrain TLR9 signaling, reduce dendritic cell activation, and polarize myelin-specific T cells toward tolerogenic phenotype and function. In mice, iPEMs blunt myelin-triggered inflammatory responses, expand regulatory T cells, and eliminate disease in a common model of MS. Finally, in samples from human MS patients, iPEMs bias myelin-triggered immune cell function toward tolerance. This work represents a unique opportunity to use PEMs to regulate immune function and promote tolerance, supporting iPEMs as a carrier-free platform to alter TLR function to reduce inflammation and combat autoimmunity.

Entities:  

Keywords:  autoimmunity and tolerance; biomaterials; human patients and clinical data; immunology and vaccines; nanotechnology; polyelectrolyte multilayers; self-assembly

Year:  2016        PMID: 27579996      PMCID: PMC6291352          DOI: 10.1021/acsnano.6b04001

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  43 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

Authors:  Samantha L Bailey; Bettina Schreiner; Eileen J McMahon; Stephen D Miller
Journal:  Nat Immunol       Date:  2007-01-07       Impact factor: 25.606

3.  Antigen kinetics determines immune reactivity.

Authors:  Pål Johansen; Tazio Storni; Lorna Rettig; Zhiyong Qiu; Ani Der-Sarkissian; Kent A Smith; Vania Manolova; Karl S Lang; Gabriela Senti; Beat Müllhaupt; Tilman Gerlach; Roberto F Speck; Adrian Bot; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

4.  Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis.

Authors:  Marco Prinz; Folker Garbe; Hauke Schmidt; Alexander Mildner; Ilona Gutcher; Karina Wolter; Matthias Piesche; Roland Schroers; Elisabeth Weiss; Carsten J Kirschning; Christian D P Rochford; Wolfgang Brück; Burkhard Becher
Journal:  J Clin Invest       Date:  2006-01-26       Impact factor: 14.808

5.  Matrix polyelectrolyte microcapsules: new system for macromolecule encapsulation.

Authors:  Dmitry V Volodkin; Alexander I Petrov; Michelle Prevot; Gleb B Sukhorukov
Journal:  Langmuir       Date:  2004-04-13       Impact factor: 3.882

6.  A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease.

Authors:  Peggy P Ho; Paulo Fontoura; Michael Platten; Raymond A Sobel; Jason J DeVoss; Lowen Y Lee; Brian A Kidd; Beren H Tomooka; Julien Capers; Ashish Agrawal; Rohit Gupta; Jonathan Zernik; Michael K Yee; Byung J Lee; Hideki Garren; William H Robinson; Lawrence Steinman
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

7.  An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems.

Authors:  Peggy P Ho; Paulo Fontoura; Pedro J Ruiz; Lawrence Steinman; Hideki Garren
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

8.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome.

Authors:  Fiona A Sharp; Darren Ruane; Benjamin Claass; Emma Creagh; James Harris; Padma Malyala; Manomohan Singh; Derek T O'Hagan; Virginie Pétrilli; Jurg Tschopp; Luke A J O'Neill; Ed C Lavelle
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-12       Impact factor: 11.205

9.  Protein encapsulation via porous CaCO3 microparticles templating.

Authors:  Dmitry V Volodkin; Natalia I Larionova; Gleb B Sukhorukov
Journal:  Biomacromolecules       Date:  2004 Sep-Oct       Impact factor: 6.988

10.  Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis.

Authors:  Marloes van Zwam; Ruth Huizinga; Nicole Heijmans; Marjan van Meurs; Annet F Wierenga-Wolf; Marie-José Melief; Rogier Q Hintzen; Bert A 't Hart; Sandra Amor; Leonie A Boven; Jon D Laman
Journal:  J Pathol       Date:  2009-03       Impact factor: 7.996

View more
  25 in total

1.  Engineering Biomaterials to Direct Innate Immunity.

Authors:  R S Oakes; E Froimchuk; C M Jewell
Journal:  Adv Ther (Weinh)       Date:  2019-02-27

2.  Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling.

Authors:  Hong Yang; Shan Yu Fung; Aihua Bao; Qiang Li; Stuart E Turvey
Journal:  J Vis Exp       Date:  2017-07-26       Impact factor: 1.355

Review 3.  Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy.

Authors:  Qin Zeng; Christopher M Jewell
Journal:  Curr Opin Biotechnol       Date:  2019-03-01       Impact factor: 9.740

4.  Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.

Authors:  Chunsong Yu; Myunggi An; Evan Jones; Haipeng Liu
Journal:  Pharm Res       Date:  2018-02-08       Impact factor: 4.200

5.  Self-Assembly as a Molecular Strategy to Improve Immunotherapy.

Authors:  Eugene Froimchuk; Sean T Carey; Camilla Edwards; Christopher M Jewell
Journal:  Acc Chem Res       Date:  2020-10-19       Impact factor: 22.384

Review 6.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

Review 7.  Linking autoantigen properties to mechanisms of immunity.

Authors:  J Daniel Griffin; Jimmy Y Song; Joshua O Sestak; Brandon J DeKosky; Cory J Berkland
Journal:  Adv Drug Deliv Rev       Date:  2020-04-20       Impact factor: 15.470

8.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

9.  Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity.

Authors:  Krystina L Hess; James I Andorko; Lisa H Tostanoski; Christopher M Jewell
Journal:  Biomaterials       Date:  2016-11-30       Impact factor: 12.479

Review 10.  Engineering Immune Tolerance with Biomaterials.

Authors:  Joshua M Gammon; Christopher M Jewell
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.